Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Revance Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RVNC
Nasdaq
8731
https://www.revance.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Revance Therapeutics Inc
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
- Apr 12th, 2024 12:00 pm
Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company
- Apr 12th, 2024 11:35 am
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 27th, 2024 8:05 pm
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
- Mar 4th, 2024 2:25 pm
Revance Announces Proposed Public Offering of Common Stock
- Mar 4th, 2024 11:37 am
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript
- Mar 2nd, 2024 1:23 pm
US$16.33: That's What Analysts Think Revance Therapeutics, Inc. (NASDAQ:RVNC) Is Worth After Its Latest Results
- Mar 2nd, 2024 12:45 pm
Revance Therapeutics Full Year 2023 Earnings: Beats Expectations
- Mar 1st, 2024 10:47 am
Q4 2023 Revance Therapeutics Inc Earnings Call
- Feb 29th, 2024 11:41 am
Revance Therapeutics Inc (RVNC) Reports Strong Revenue Growth in Q4 and Full Year 2023
- Feb 28th, 2024 9:43 pm
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
- Feb 28th, 2024 9:05 pm
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
- Feb 21st, 2024 1:01 pm
Revance to Participate in Upcoming Investor Conferences
- Feb 21st, 2024 1:00 pm
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
- Feb 20th, 2024 10:10 pm
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
- Feb 2nd, 2024 1:00 pm
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
- Feb 1st, 2024 1:00 pm
Shareholders in Revance Therapeutics (NASDAQ:RVNC) are in the red if they invested a year ago
- Jan 30th, 2024 12:05 pm
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
- Jan 8th, 2024 1:00 pm
Analysts Just Slashed Their Revance Therapeutics, Inc. (NASDAQ:RVNC) EPS Numbers
- Nov 10th, 2023 10:06 am
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript
- Nov 10th, 2023 12:05 am
Scroll